2026 Q1 -tulosraportti
Vain PDF
109 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·55 min sittenHey everyone❤️ I'll be completely honest and say that I have very little understanding of such small companies and shares in small companies, I learn a lot by reading in the comment section here and reading reports occasionally, but to those of you who know this better than average, how CAN this share price look towards the year '27? With good results this week now? What can the share price be?
·6 t sittenDicot Pharma submits Phase 2b application in EU Close Today at 09:15 ∙ Finwire Smallcap Dicot Pharma 2.30% Research company Dicot Pharma has submitted a clinical trial application in the EU for the Phase 2b study with the drug candidate LIB-01, which is being developed for erectile dysfunction. The study will be conducted in the USA and Europe and evaluate the effect of LIB-01 at different doses after repeated dosing. The purpose is to provide a basis for dose selection before Phase 3. Dicot received clearance from the FDA in June to initiate the first part of the study in the USA, where study start is planned for the second half of 2026. A decision on the European application is expected during the fourth quarter. "That the application has now been submitted in the EU is an important milestone, and we look forward to advancing the study in both the USA and Europe," says CEO Elin Trampe. The study is planned with an adaptive design and at least 200 participants.
·2 päivää sittenGot some help from AI to understand the result from the last test 2a. You are absolutely right in your clarification – and that is a very important detail. The primary goal (primary endpoint) for the entire patient group as a whole did not reach statistical significance over placebo at week 4. The reason why the company and the market nevertheless considered the study a success is due to the results in the specific subgroups and doses:The low dose failed: The lowest dose of 10 mg provided no clinically relevant improvement. This pulled down the overall average. Strong placebo effect at the start: At week 4, the placebo group experienced a significant improvement, which made it difficult for the medicine to statistically differentiate itself across the entire group. Statistical success at week 8: The placebo effect diminished over time. At week 8, a combination of the two highest doses (25 mg and 50 mg) showed a statistically significant improvement compared to placebo (p<0.05).Highest dose (50 mg): Among patients with moderate erectile dysfunction, 31% achieved a full effect (normalized function) in the 50 mg group, compared to 0% in the placebo group. Dicot Pharma's CEO therefore downplayed the missed primary endpoint because the study was a smaller phase 2a "Proof of Concept" study designed to find the right dose. The company is now using the data to directly pursue the higher doses in the upcoming phase 2b study.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
109 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·55 min sittenHey everyone❤️ I'll be completely honest and say that I have very little understanding of such small companies and shares in small companies, I learn a lot by reading in the comment section here and reading reports occasionally, but to those of you who know this better than average, how CAN this share price look towards the year '27? With good results this week now? What can the share price be?
- ·6 t sittenDicot Pharma submits Phase 2b application in EU Close Today at 09:15 ∙ Finwire Smallcap Dicot Pharma 2.30% Research company Dicot Pharma has submitted a clinical trial application in the EU for the Phase 2b study with the drug candidate LIB-01, which is being developed for erectile dysfunction. The study will be conducted in the USA and Europe and evaluate the effect of LIB-01 at different doses after repeated dosing. The purpose is to provide a basis for dose selection before Phase 3. Dicot received clearance from the FDA in June to initiate the first part of the study in the USA, where study start is planned for the second half of 2026. A decision on the European application is expected during the fourth quarter. "That the application has now been submitted in the EU is an important milestone, and we look forward to advancing the study in both the USA and Europe," says CEO Elin Trampe. The study is planned with an adaptive design and at least 200 participants.
- ·2 päivää sittenGot some help from AI to understand the result from the last test 2a. You are absolutely right in your clarification – and that is a very important detail. The primary goal (primary endpoint) for the entire patient group as a whole did not reach statistical significance over placebo at week 4. The reason why the company and the market nevertheless considered the study a success is due to the results in the specific subgroups and doses:The low dose failed: The lowest dose of 10 mg provided no clinically relevant improvement. This pulled down the overall average. Strong placebo effect at the start: At week 4, the placebo group experienced a significant improvement, which made it difficult for the medicine to statistically differentiate itself across the entire group. Statistical success at week 8: The placebo effect diminished over time. At week 8, a combination of the two highest doses (25 mg and 50 mg) showed a statistically significant improvement compared to placebo (p<0.05).Highest dose (50 mg): Among patients with moderate erectile dysfunction, 31% achieved a full effect (normalized function) in the 50 mg group, compared to 0% in the placebo group. Dicot Pharma's CEO therefore downplayed the missed primary endpoint because the study was a smaller phase 2a "Proof of Concept" study designed to find the right dose. The company is now using the data to directly pursue the higher doses in the upcoming phase 2b study.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
109 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·55 min sittenHey everyone❤️ I'll be completely honest and say that I have very little understanding of such small companies and shares in small companies, I learn a lot by reading in the comment section here and reading reports occasionally, but to those of you who know this better than average, how CAN this share price look towards the year '27? With good results this week now? What can the share price be?
- ·6 t sittenDicot Pharma submits Phase 2b application in EU Close Today at 09:15 ∙ Finwire Smallcap Dicot Pharma 2.30% Research company Dicot Pharma has submitted a clinical trial application in the EU for the Phase 2b study with the drug candidate LIB-01, which is being developed for erectile dysfunction. The study will be conducted in the USA and Europe and evaluate the effect of LIB-01 at different doses after repeated dosing. The purpose is to provide a basis for dose selection before Phase 3. Dicot received clearance from the FDA in June to initiate the first part of the study in the USA, where study start is planned for the second half of 2026. A decision on the European application is expected during the fourth quarter. "That the application has now been submitted in the EU is an important milestone, and we look forward to advancing the study in both the USA and Europe," says CEO Elin Trampe. The study is planned with an adaptive design and at least 200 participants.
- ·2 päivää sittenGot some help from AI to understand the result from the last test 2a. You are absolutely right in your clarification – and that is a very important detail. The primary goal (primary endpoint) for the entire patient group as a whole did not reach statistical significance over placebo at week 4. The reason why the company and the market nevertheless considered the study a success is due to the results in the specific subgroups and doses:The low dose failed: The lowest dose of 10 mg provided no clinically relevant improvement. This pulled down the overall average. Strong placebo effect at the start: At week 4, the placebo group experienced a significant improvement, which made it difficult for the medicine to statistically differentiate itself across the entire group. Statistical success at week 8: The placebo effect diminished over time. At week 8, a combination of the two highest doses (25 mg and 50 mg) showed a statistically significant improvement compared to placebo (p<0.05).Highest dose (50 mg): Among patients with moderate erectile dysfunction, 31% achieved a full effect (normalized function) in the 50 mg group, compared to 0% in the placebo group. Dicot Pharma's CEO therefore downplayed the missed primary endpoint because the study was a smaller phase 2a "Proof of Concept" study designed to find the right dose. The company is now using the data to directly pursue the higher doses in the upcoming phase 2b study.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt